Agilent Technologies Denmark ApS recalls FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) and 2 other products
FDA assigned 3 recall numbers to the action, one per product; all of them are listed with this filing.
Agilent Technologies Denmark ApS began a medical device recall on August 11, 2025 whose reported distribution included Ohio. FDA
What the record shows
The stated reason: Their is the potential for weak staining which may result in false negative CD20 identification. FDA graded it Class II — use may cause temporary or medically reversible health consequences. Quantity affected: 4145. The recall is listed as ongoing. FDA
Context
By the numbers
- Date of record: August 11, 2025 FDA
- Recall number: Z-2563-2025 FDA
- Recalls in this action: 3 FDA
- Recalling firm: Agilent Technologies Denmark ApS FDA
- Product: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number… FDA
- Reason for recall: Their is the potential for weak staining which may result in false negative CD20 identification. FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | Z-2563-2025 |
|---|---|
| Recalls in this action | 3 |
| Recalling firm | Agilent Technologies Denmark ApS |
| Product | Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2 Software Version: Not applicable Product Description: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) is intended for use in immunohistochemistry together with the Dako Omnis instrument. This antibody labels cells of the B-cell lineage and is a useful aid for the classification of neoplasms of B-cell derivation. Component: Not applicable |
| Reason for recall | Their is the potential for weak staining which may result in false negative CD20 identification. |
| Classification | Class II — use may cause temporary or medically reversible health consequences |
| Recall type | medical device |
| Quantity | 4145 |
| Status | Ongoing |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20250811 |
| Reported | 20250924 |
| Distribution | US Nationwide distribution including in the states of Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, Wiscon |
| Firm location | Glostrup, N/A, Denmark |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.